The P-III (BE BRIGHT) OLE study evaluating bimekizumab (320mg, q4w or q8w) in 1355 adult patients with mod. to sev. PsO. The results showed that 8 out of 10 patients maintained PASI 100 response & health-related QoL outcomes who achieved complete skin clearance (PASI 100) @16wks.
In all bimekizumab-randomized patients in (BE SURE, BE VIVID and BE READY) studies & patients with (BE SURE & BE READY), 89.3% & 93.6% achieved PASI 100 @1yr. & 82.0% & 84.4% @3yr. among 16wk. PASI 100 responders; 96.5% & 98.9% achieved PASI ≤2 @1yr. & 94.2% & 96.8% @3yr.; 92.0% & 95.8% achieved DLQI 0/1 @1yr. & 88.0% & 92.5% @3yr.
The pooled safety data from ~3yrs. of treatment in P-II/III trials showed bimekizumab was well tolerated with no new safety signals
Ref: PRNewswire | Image: UCB
